AI Article Synopsis
- - The study focuses on managing venous thromboembolism (VTE) in advanced lung cancer patients, highlighting its importance for treatment choices and overall prognosis.
- - Researchers developed a new scoring system to predict VTE risk specifically for advanced lung cancer using data from over 1000 patients, with a key finding that 9.9% of them experienced VTE.
- - The scoring model includes factors like sex, cancer type, and certain blood counts, with a score of 5 or more indicating a high risk for VTE, helping identify patients who may need closer monitoring.
Article Abstract
Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981807 | PMC |
| http://dx.doi.org/10.1186/s13045-022-01259-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!